Lesson plan
Priority review
Priority review is a designation granted by the U.S. Food and Drug Administration (FDA) to certain drug applications that, if approved, would provide significant improvements in the treatment, diagnosis, or prevention of serious conditions. Under this designation, the FDA aims to take action on an application within six months, compared to ten months under standard review. Priority review does not change the standards for approval or the amount of evidence required to demonstrate a drug's safety and effectiveness. Instead, it allows the FDA to allocate additional resources to the evaluation of promising therapies. The designation is one of several expedited programs used by the FDA to facilitate the development and review of drugs that address unmet medical needs. Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. The priority review voucher program is a program that grants a voucher for priority review to a drug developer as an incentive to develop treatments for disease indications with limited profitability.…
Article summary
Priority review is a designation granted by the U.S. Food and Drug Administration (FDA) to certain drug applications that, if approved, would provide significant improvements in the treatment, diagnosis, or prevention of serious conditions. Under this designation, the FDA aims to take action on an application within six months, compared to ten months under standard review. Priority review does not change the standards for approval or the amount of evidence required to demonstrate a drug's safety and effectiveness. Instead, it allows the FDA to allocate additional resources to the evaluation of promising therapies. The designation is one of several expedited programs used by the FDA to facilitate the development and review of drugs that address unmet medical needs. Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. The priority review voucher program is a program that grants a voucher for priority review to a drug developer as an incentive to develop treatments for disease indications with limited profitability.…
Key claims
- publication date: 2006 — source: Wikipedia · confidence 0.95
- publication date: 2008 — source: Wikipedia · confidence 0.95
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- The record states that the publication date is "2006". What evidence would count against this claim?
- The record states that the publication date is "2008". What evidence would count against this claim?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
- Wikipedia https://en.wikipedia.org/w/index.php?oldid=1352827092
Key claims and bibliography are generated from the same tracked claims and sources as the article page.